Cargando…

The clinical impact of removing rectal gas on high‐dose‐rate brachytherapy dose distributions for gynecologic cancers

PURPOSE: To evaluate the impact of gas removal on bladder and rectal doses during intracavitary and interstitial high‐dose‐rate brachytherapy (HDRB) for gynecologic cancers. MATERIAL AND METHODS: Fifteen patients treated with definitive external beam radiation followed by HDRB for gynecologic cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergalasova, Irina, Ennis, Ronald D., Sayan, Mutlay, Liu, Bo, Yue, Ning J., Hathout, Lara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882092/
https://www.ncbi.nlm.nih.gov/pubmed/33440079
http://dx.doi.org/10.1002/acm2.13132
_version_ 1783650990654750720
author Vergalasova, Irina
Ennis, Ronald D.
Sayan, Mutlay
Liu, Bo
Yue, Ning J.
Hathout, Lara
author_facet Vergalasova, Irina
Ennis, Ronald D.
Sayan, Mutlay
Liu, Bo
Yue, Ning J.
Hathout, Lara
author_sort Vergalasova, Irina
collection PubMed
description PURPOSE: To evaluate the impact of gas removal on bladder and rectal doses during intracavitary and interstitial high‐dose‐rate brachytherapy (HDRB) for gynecologic cancers. MATERIAL AND METHODS: Fifteen patients treated with definitive external beam radiation followed by HDRB for gynecologic cancers for a total of 21 fractions, presented with a significant amount of rectal gas at initial CT imaging (CT(GAS)) after implantation. The gas was removed via rectal tubing followed by subsequent scan acquisition (CT(CLINICAL)), which was used for planning and treatment delivery. To assess the effect of gas removal on dosimetry, both bladder and rectum volumes were recontoured on CT(GAS). In order to evaluate the clinical impact on the total Equivalent‐Dose‐in‐2Gy‐fraction (EQD(2)), each fraction was also replanned to maintain clinically delivered target coverage (HRCTV D90). EQD(2) D2cm(3) for bladder and rectum were compared between plans. The Wilcoxon signed rank test was performed to evaluate statistically significant differences for all comparisons (P < 0.05). RESULTS: Mean rectum and bladder D(max), D0.1cm(3), D1cm(3), D2cm(3), and D5cm(3) were significantly different between CT(GAS) and CT(CLINICAL). The mean percent increases on CT(GAS) for bladder were 12.3, 8.4, 9.9, 10.2, and 9.5% respectively and for rectum were 27.0, 19.6, 18.1, 18.5, and 19.4%, respectively. After replanning with CT(GAS) to maintain HRCTV D90 EQD(2), bladder and rectum EQD(2) D2 cm(3) resulted in significantly higher doses. The mean EQD(2) D2 cm(3) difference was 2.4 and 4.1 Gy for bladder and rectum, revealing a higher impact of gas removal on rectal DVH. CONCLUSION: Rectal gas removal resulted in statistically significant differences for both bladder and rectum. The resulting larger EQD(2) D2 cm(3) for bladder and rectum demonstrates that if patients were treated without removing gas, target coverage would need to be sacrificed to satisfy the rectum constraints and prevent toxicities. Therefore, this study demonstrates the importance of gas removal for gynecologic HDRB patients.
format Online
Article
Text
id pubmed-7882092
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78820922021-02-19 The clinical impact of removing rectal gas on high‐dose‐rate brachytherapy dose distributions for gynecologic cancers Vergalasova, Irina Ennis, Ronald D. Sayan, Mutlay Liu, Bo Yue, Ning J. Hathout, Lara J Appl Clin Med Phys Radiation Oncology Physics PURPOSE: To evaluate the impact of gas removal on bladder and rectal doses during intracavitary and interstitial high‐dose‐rate brachytherapy (HDRB) for gynecologic cancers. MATERIAL AND METHODS: Fifteen patients treated with definitive external beam radiation followed by HDRB for gynecologic cancers for a total of 21 fractions, presented with a significant amount of rectal gas at initial CT imaging (CT(GAS)) after implantation. The gas was removed via rectal tubing followed by subsequent scan acquisition (CT(CLINICAL)), which was used for planning and treatment delivery. To assess the effect of gas removal on dosimetry, both bladder and rectum volumes were recontoured on CT(GAS). In order to evaluate the clinical impact on the total Equivalent‐Dose‐in‐2Gy‐fraction (EQD(2)), each fraction was also replanned to maintain clinically delivered target coverage (HRCTV D90). EQD(2) D2cm(3) for bladder and rectum were compared between plans. The Wilcoxon signed rank test was performed to evaluate statistically significant differences for all comparisons (P < 0.05). RESULTS: Mean rectum and bladder D(max), D0.1cm(3), D1cm(3), D2cm(3), and D5cm(3) were significantly different between CT(GAS) and CT(CLINICAL). The mean percent increases on CT(GAS) for bladder were 12.3, 8.4, 9.9, 10.2, and 9.5% respectively and for rectum were 27.0, 19.6, 18.1, 18.5, and 19.4%, respectively. After replanning with CT(GAS) to maintain HRCTV D90 EQD(2), bladder and rectum EQD(2) D2 cm(3) resulted in significantly higher doses. The mean EQD(2) D2 cm(3) difference was 2.4 and 4.1 Gy for bladder and rectum, revealing a higher impact of gas removal on rectal DVH. CONCLUSION: Rectal gas removal resulted in statistically significant differences for both bladder and rectum. The resulting larger EQD(2) D2 cm(3) for bladder and rectum demonstrates that if patients were treated without removing gas, target coverage would need to be sacrificed to satisfy the rectum constraints and prevent toxicities. Therefore, this study demonstrates the importance of gas removal for gynecologic HDRB patients. John Wiley and Sons Inc. 2021-01-13 /pmc/articles/PMC7882092/ /pubmed/33440079 http://dx.doi.org/10.1002/acm2.13132 Text en © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Vergalasova, Irina
Ennis, Ronald D.
Sayan, Mutlay
Liu, Bo
Yue, Ning J.
Hathout, Lara
The clinical impact of removing rectal gas on high‐dose‐rate brachytherapy dose distributions for gynecologic cancers
title The clinical impact of removing rectal gas on high‐dose‐rate brachytherapy dose distributions for gynecologic cancers
title_full The clinical impact of removing rectal gas on high‐dose‐rate brachytherapy dose distributions for gynecologic cancers
title_fullStr The clinical impact of removing rectal gas on high‐dose‐rate brachytherapy dose distributions for gynecologic cancers
title_full_unstemmed The clinical impact of removing rectal gas on high‐dose‐rate brachytherapy dose distributions for gynecologic cancers
title_short The clinical impact of removing rectal gas on high‐dose‐rate brachytherapy dose distributions for gynecologic cancers
title_sort clinical impact of removing rectal gas on high‐dose‐rate brachytherapy dose distributions for gynecologic cancers
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882092/
https://www.ncbi.nlm.nih.gov/pubmed/33440079
http://dx.doi.org/10.1002/acm2.13132
work_keys_str_mv AT vergalasovairina theclinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT ennisronaldd theclinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT sayanmutlay theclinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT liubo theclinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT yueningj theclinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT hathoutlara theclinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT vergalasovairina clinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT ennisronaldd clinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT sayanmutlay clinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT liubo clinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT yueningj clinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers
AT hathoutlara clinicalimpactofremovingrectalgasonhighdoseratebrachytherapydosedistributionsforgynecologiccancers